{
    "symbol": "JAGX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 11:54:04",
    "content": " To recap, in approximately six to nine months, we expect to have completion of enrollment in our Phase III trial of cancer therapy-related diarrhea, called the OnTarget trial, and published proof of concept data in support of potential early access program participation in mid-2023 in Europe for SBS and/or CDD, which could bring in meaningful revenues while Crofelemer continues to go through the process for full approval in Europe, two expected transformative events on the near term horizon supporting value recognition, potentially moving initiatives from a pipeline opportunity to ultimately tangible revenues, further tangible revenues in hand for Crofelemer."
}